ASLAN Pharmaceuticals

You are now leaving our web site.
I understand
Program Target Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated milestones in 2024
IL-13Rα1 Atopic dermatitis
Biologic naïve
Selection of partner to advance eblasakimab into Phase 3
Dupilumab experienced
Topline readout from dupilumab-experienced trial
Type 2-driven disease
DHODH Alopecia areata
Phase 2a interim topline data mid-2024


Eblasakimab

Phase 2

Potential first-in-class antibody targeting the IL 13 receptor in moderate-to-severe atopic dermatitis

Read more about Eblasakimab

Farudodstat

Phase 2

Potent, oral DHODH inhibitor with the potential to be a first-in-class treatment for alopecia areata

Read more about Farudodstat

Therapeutic Areas

We focus on atopic dermatitis, alopecia areata and Type 2-driven diseases.

Atopic dermatitis

Atopic dermatitis

Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.